Brokerages expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to announce ($0.95) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Five Prime Therapeutics’ earnings, with estimates ranging from ($1.11) to ($0.72). Five Prime Therapeutics posted earnings of ($1.37) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 30.7%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, November 5th.
On average, analysts expect that Five Prime Therapeutics will report full-year earnings of ($3.91) per share for the current fiscal year, with EPS estimates ranging from ($4.27) to ($3.65). For the next year, analysts expect that the firm will post earnings of ($2.76) per share, with EPS estimates ranging from ($3.95) to ($1.79). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.09). The business had revenue of $3.33 million for the quarter, compared to the consensus estimate of $5.53 million. Five Prime Therapeutics had a negative net margin of 842.84% and a negative return on equity of 62.13%.
FPRX has been the topic of a number of recent research reports. Wells Fargo & Co downgraded shares of Five Prime Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $35.00 to $10.00 in a report on Monday, June 3rd. Roth Capital initiated coverage on shares of Five Prime Therapeutics in a report on Wednesday, May 29th. They set a “neutral” rating and a $10.00 price target on the stock. ValuEngine upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. Five Prime Therapeutics presently has an average rating of “Hold” and a consensus target price of $16.00.
Shares of Five Prime Therapeutics stock traded down $0.13 during midday trading on Friday, reaching $5.72. 181,400 shares of the company’s stock traded hands, compared to its average volume of 366,285. The company has a market cap of $218.11 million, a price-to-earnings ratio of -1.38 and a beta of 2.59. The company’s 50 day simple moving average is $5.48 and its 200 day simple moving average is $8.58. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.87 and a current ratio of 6.87. Five Prime Therapeutics has a 52 week low of $4.89 and a 52 week high of $14.60.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Walleye Trading Advisors LLC bought a new position in Five Prime Therapeutics in the 2nd quarter worth $286,000. Walleye Trading LLC bought a new position in Five Prime Therapeutics in the 2nd quarter worth $314,000. Nuveen Asset Management LLC bought a new position in Five Prime Therapeutics in the 2nd quarter worth $3,128,000. Jane Street Group LLC bought a new position in Five Prime Therapeutics in the 2nd quarter worth $311,000. Finally, Citadel Advisors LLC raised its holdings in Five Prime Therapeutics by 508.2% in the 2nd quarter. Citadel Advisors LLC now owns 157,475 shares of the biotechnology company’s stock worth $950,000 after acquiring an additional 131,583 shares during the period. Hedge funds and other institutional investors own 74.31% of the company’s stock.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.